Literature DB >> 14705169

KATP channel openers: structure-activity relationships and therapeutic potential.

Raimund Mannhold1.   

Abstract

ATP-sensitive potassium channels (K(ATP) channels) are heteromeric complexes of pore-forming inwardly rectifying potassium channel subunits and regulatory sulfonylurea receptor subunits. K(ATP) channels were identified in a variety of tissues including muscle cells, pancreatic beta-cells, and various neurons. They are regulated by the intracellular ATP/ADP ratio; ATP induces channel inhibition and MgADP induces channel opening. Functionally, K(ATP) channels provide a means of linking the electrical activity of a cell to its metabolic state. Shortening of the cardiac action potential, smooth muscle relaxation, inhibition of both insulin secretion, and neurotransmitter release are mediated via K(ATP) channels. Given their many physiological functions, K(ATP) channels represent promising drug targets. Sulfonylureas like glibenclamide block K(ATP) channels; they are used in the therapy of type 2 diabetes. Openers of K(ATP) channels (KCOs), for example, relax smooth muscle and induce hypotension. KCOs are chemically heterogeneous and include as different classes as the benzopyrans, cyanoguanidines, thioformamides, thiadiazines, and pyridyl nitrates. Examples for new chemical entities more recently developed as KCOs include cyclobutenediones, dihydropyridine related structures, and tertiary carbinols. Copyright 2003 Wiley Periodicals, Inc

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14705169     DOI: 10.1002/med.10060

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  43 in total

1.  Vasorelaxing effects of flavonoids: investigation on the possible involvement of potassium channels.

Authors:  Vincenzo Calderone; Silvio Chericoni; Cinzia Martinelli; Lara Testai; Antonio Nardi; Ivano Morelli; Maria Cristina Breschi; Enrica Martinotti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-17       Impact factor: 3.000

2.  Functional roles of ATP-sensitive potassium channel as related to anesthesia.

Authors:  Takashi Kawano
Journal:  J Anesth       Date:  2011-11-19       Impact factor: 2.078

Review 3.  Muscle KATP channels: recent insights to energy sensing and myoprotection.

Authors:  Thomas P Flagg; Decha Enkvetchakul; Joseph C Koster; Colin G Nichols
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

Review 4.  Cardiac ion channels.

Authors:  Birgit T Priest; Jeff S McDermott
Journal:  Channels (Austin)       Date:  2015-08-20       Impact factor: 2.581

Review 5.  K(ATP) channel therapeutics at the bedside.

Authors:  A Jahangir; Andre Terzic
Journal:  J Mol Cell Cardiol       Date:  2005-07       Impact factor: 5.000

Review 6.  Smooth Muscle Ion Channels and Regulation of Vascular Tone in Resistance Arteries and Arterioles.

Authors:  Nathan R Tykocki; Erika M Boerman; William F Jackson
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

Review 7.  Potassium channels: a review of broadening therapeutic possibilities for neurological diseases.

Authors:  Snezana Maljevic; Holger Lerche
Journal:  J Neurol       Date:  2012-11-11       Impact factor: 4.849

8.  Celastrol Dilates and Counteracts Ethanol-Induced Constriction of Cerebral Arteries.

Authors:  Kelsey North; Alexandria Slayden; Steven Mysiewicz; Anna Bukiya; Alex Dopico
Journal:  J Pharmacol Exp Ther       Date:  2020-08-29       Impact factor: 4.030

9.  Diazoxide attenuates autoimmune encephalomyelitis and modulates lymphocyte proliferation and dendritic cell functionality.

Authors:  N Virgili; P Mancera; C Chanvillard; A Wegner; B Wappenhans; M J Rodríguez; C Infante-Duarte; J F Espinosa-Parrilla; M Pugliese
Journal:  J Neuroimmune Pharmacol       Date:  2014-06-18       Impact factor: 4.147

10.  Ca2+ -activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction.

Authors:  R González-Corrochano; Jm La Fuente; P Cuevas; A Fernández; Mx Chen; I Sáenz de Tejada; J Angulo
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.